Skip to main content

Advertisement

SpringerLink
Log in

Osteoporosis in men: Pathophysiology and treatment

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Osteoporosis has long been long considered a disease of the aging female skeleton. However, it is now clear that men are also at risk for this disorder. Epidemiologic studies have confirmed that osteoporotic fractures in men are an increasing public health problem, in part due to increased longevity and increased public awareness. Recent large-scale population studies in men have led to advances in our understanding of bone fragility and its treatment in men. This article reviews what is known about the factors in men that lead to acquisition, maintenance, and loss of bone, as well as new insights into causes, pathogenesis, and treatment of osteoporosis in men.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Cummings SR, Melton LJ: Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359:1761–1767.

    Article  PubMed  Google Scholar 

  2. Center JR, Nguyen TV, Schneider D, et al.: Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999, 353:878–882.

    Article  PubMed  CAS  Google Scholar 

  3. Cummings SR, Cawthon PM, Ensrud KE, et al.: BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 2006, 21:1550–1556.

    Article  PubMed  Google Scholar 

  4. Melton LJ: Epidemiology of fractures. In Osteoporosis: Etiology, Diagnosis and Management, 2nd edn. Edited by Riggs BL, Melton LJ. Philadelphia: Lippincott-Raven Publishers; 1995:225–247.

    Google Scholar 

  5. Seeman E, Bianchi G, Khosla S, et al.: Bone fragility in men—where are we? Osteoporos Int 2006, 17:1577–1583.

    Article  PubMed  CAS  Google Scholar 

  6. Seeman E, Delmas PD: Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250–2261.

    Article  PubMed  CAS  Google Scholar 

  7. Riggs BL, Melton LJ 3rd, Robb RA, et al.: A population-based study of age and sex differences in bone volumetric density, size, geometry and structure at different skeletal sites. J Bone Miner Res 2004, 19:1945–1954.

    Article  PubMed  Google Scholar 

  8. Chavassieux P, Meunier PJ: Histomorphometric approach of bone loss in men. Calcif Tissue Int 2001, 69:209–213.

    Article  PubMed  CAS  Google Scholar 

  9. Khosla S: Idiopathic osteoporosis—is the osteoblast to blame? [editorial] J Clin Endocrinol Metab 1997, 82:2792–2794.

    Article  PubMed  CAS  Google Scholar 

  10. Bilezikian JP: Osteoporosis in men. J Clin Endocrinol Metab 1999, 84:3431–3434.

    Article  PubMed  CAS  Google Scholar 

  11. Pernow Y, Granberg B, Saaf M, Weidenhielm L: Osteoblast dysfunction in male idiopathic osteoporosis. Calcif Tissue Int 2006, 78:90–97.

    Article  PubMed  CAS  Google Scholar 

  12. Perry HM 3rd, Fallon MD, Bergfeld M, et al.: Osteoporosis in young men. Arch Intern Med 1982, 142:1295–1298.

    Article  PubMed  Google Scholar 

  13. Seeman E, Melton LJ 3rd, O’Fallon WM, Riggs BL: Risk factors for spinal osteoporosis in men. Am J Med 1983, 75:977–982.

    Article  PubMed  CAS  Google Scholar 

  14. Cauley JA, Fullman RL, Stone KL, et al.: Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 2005, 16:1525–1537.

    Article  PubMed  Google Scholar 

  15. Looker AC, Orwoll ES, Johnston CC, et al.: Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 1997, 12:1761–1768.

    Article  PubMed  CAS  Google Scholar 

  16. Gennari L, Brandi ML: Genetics of male osteoporosis. Calcif Tissue Int 2001, 69:200–204.

    Article  PubMed  CAS  Google Scholar 

  17. Eisman JA: Genetics of osteoporosis. Endocr Rev 1999, 20:788–804.

    Article  PubMed  CAS  Google Scholar 

  18. Gennari L, Masi L, Merlotti D, et al.: A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab 2004, 89:2803–2810.

    Article  PubMed  CAS  Google Scholar 

  19. Van Pottelbergh I, Goemaere S, Kaufman JM: Bioavailable estradiol and arom at ase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 2003, 88:3075–3081.

    Article  PubMed  CAS  Google Scholar 

  20. Ferrari SL, Deutsch S, Baudoin C, et al.: LRP5 gene polymorphisms and idiopathic osteoporosis in men. Bone 2005, 37:770–775.

    Article  PubMed  CAS  Google Scholar 

  21. Rosen CJ, Kurland ES, Vereault D, et al.: An association between serum IGF-1 and a simple sequence repeat in the IGF-1 gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998, 83:2286–2290.

    Article  PubMed  CAS  Google Scholar 

  22. Lamberts SW, van den Beld AW, van der Lely A: The endocrinology of aging. Science 1997, 278:419–424.

    Article  PubMed  CAS  Google Scholar 

  23. Gray A, Feldman HA, McKinlay JB, Longcope C: Age, disease and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J Clin Endocrinol Metab 1991, 73:1016–1025.

    Article  PubMed  CAS  Google Scholar 

  24. Orwoll E, Lambert LC, Marshall LM, et al.: Testoster one and estradiol among older men. J Clin Endocrinol Metab 2006, 91:1336–1344.

    Article  PubMed  CAS  Google Scholar 

  25. Khosla S, Melton LJ 3rd, Riggs BL: Clinical review 144: Estrogen and the male skeleton. J Clin Endocrinol Metab 2002, 87:1443–1450.

    Article  PubMed  CAS  Google Scholar 

  26. Slemenda CW, Longcope C, Zhou L, et al.: Sex steroids and bone mass in older men: positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997, 100:1755–1759.

    Article  PubMed  CAS  Google Scholar 

  27. Khosla S, Melton LJ 3rd, Atkinson EJ, O’Fallon WM: Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001, 86:3555–3561.

    Article  PubMed  CAS  Google Scholar 

  28. Gennari L, Merlotti D, Martini G, et al.: Longitudinal association between sex horm one levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 2003, 88:5327–5333.

    Article  PubMed  CAS  Google Scholar 

  29. Szulc P, Munoz F, Claustrat B, et al.: Bioavailable estradiol may be an important determinant of osteoporosis in men. The MINOS Study. J Clin Endocrinol Metab 2001, 86:192–199.

    Article  PubMed  CAS  Google Scholar 

  30. Khosla S, Melton LJ 3rd, Robb RA, et al.: Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. J Bone Miner Res 2005, 20:730–740.

    Article  PubMed  Google Scholar 

  31. Gennari L, Nuti R, Bilezikian JP: Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 2004, 89:5898–5907.

    Article  PubMed  CAS  Google Scholar 

  32. Ensrud KE, Lewis CE, Lambert LC, et al.: Endogenous sex steroids, weight change and rates of hip bone loss in older men: the MrOS study. Osteoporos Int 2006, 17:1329–1336.

    Article  PubMed  CAS  Google Scholar 

  33. Crave JC, Lejeune H, Brebant C, et al.: Differential effects of insulin-like growth factor I on the production of plasma steroid-binding globulins by human hepatoblastoma-derived (HepG2) cells. J Clin Endocrinol Metab 1995, 80:1283–1289.

    Article  PubMed  CAS  Google Scholar 

  34. Kurland ES, Rosen CJ, Cosman F, et al.: Insulin-like growth factor-1 men with idiopathic osteoporosis. J Clin Endocrinol Metab 1997, 82:2799–2805.

    Article  PubMed  CAS  Google Scholar 

  35. Kurland ES, Chan FK, Rosen CJ, Bilezikian JP: Normal growth horm one secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-1. J Clin Endocrinol Metab 1998, 83:2576–2579.

    Article  PubMed  CAS  Google Scholar 

  36. Rosen CJ, Kurland ES, Vereault D, et al.: An association between serum IGF-1 and a simple sequence repeat in the IGF-1 gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998, 83:2286–2290.

    Article  PubMed  CAS  Google Scholar 

  37. Khosla S, Melton LJ 3rd, Achenbach SJ, et al.: Hormonal and biochemical determinants of trabecular microstructure at the ultradistal radius in women and men. J Clin Endocrinol Metab 2006, 91:885–891.

    Article  PubMed  CAS  Google Scholar 

  38. Boullion R, Bex M, Vanderschueren D, Boonen S: Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab 2004, 89:6025–6029.

    Article  CAS  Google Scholar 

  39. Kousteni S, Chen JR, Bellido T, et al.: Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 2002, 298:843–846.

    Article  PubMed  CAS  Google Scholar 

  40. Lewiecki EM, Watts NB, McClung MR, et al.: Official positions of the International Society for Clinical Densitometry. J Clin Endocrinol Metab 2004, 89:3651–3655.

    Article  PubMed  CAS  Google Scholar 

  41. Kiebzak GM, Beinart GA, Perser K, et al.: Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002, 162:2217–2222.

    Article  PubMed  Google Scholar 

  42. Feldstein AC, Nichols G, Orwoll E, et al.: The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 2005, 16:953–962.

    Article  PubMed  Google Scholar 

  43. Orwoll ES: Treatment of osteoporosis in men [review]. Calcif Tissue Int 2004, 75:114–119.

    Article  PubMed  CAS  Google Scholar 

  44. Orwoll E, Ettinger M, Weiss S, et al.: Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604–610.

    Article  PubMed  CAS  Google Scholar 

  45. Ringe ID, Faber H, Dorst A: Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001, 86:5252–5255.

    Article  PubMed  CAS  Google Scholar 

  46. Hodsman AB, Bauer DC, Dempster DW, et al.: Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005, 26:688–703.

    Article  PubMed  CAS  Google Scholar 

  47. Kurland ES, Cosman F, McMahon DJ, et al.: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85:3069–3076.

    Article  PubMed  CAS  Google Scholar 

  48. Kaufman JM, Orwoll E, Goemaere S, et al.: Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005, 16:510–516.

    Article  PubMed  CAS  Google Scholar 

  49. Bilezikian JP, Rubin MR: Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis. Curr Osteoporos Rep 2006, 4:5–13.

    Article  PubMed  Google Scholar 

  50. Tracz MJ, Sideras K, Bolona ER, et al.: Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006, 91:2011–2016.

    Article  PubMed  CAS  Google Scholar 

  51. Gennari L, Nuti R, Bilezikian JP: Estrogen in men: effects on bone accrual, maintenance and prevention of bone loss. Exp Rev Endocrinol Metab 2006, 1:281–295.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Physicians and Surgeons, 630 W. 168th Street, New York, NY, 10032, USA

    John P. Bilezikian MD

Authors
  1. Luigi Gennari MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John P. Bilezikian MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John P. Bilezikian MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gennari, L., Bilezikian, J.P. Osteoporosis in men: Pathophysiology and treatment. Curr Rheumatol Rep 9, 71–77 (2007). https://doi.org/10.1007/s11926-007-0025-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-007-0025-y

Keywords

Search

Navigation